ENLV - CIK 0001596812
Enlivex Therapeutics Ltd. trades as ENLV. This page tracks Enlivex Therapeutics Ltd. through 393 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| 6-K | - | 2026-05-28 |
| 6-K | - | 2026-05-27 |
| 6-K | - | 2026-05-18 |
| 6-K | - | 2026-05-15 |
| 424B3 | - | 2026-05-01 |
| EFFECT | - | 2026-04-30 |
| F-3 | - | 2026-04-21 |
| 6-K | - | 2026-04-21 |
The largest companies sharing Enlivex Therapeutics Ltd.'s SEC industry classification (pharmaceutical preparations).
Yes. Enlivex Therapeutics Ltd. reported net income of $1.24B in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.